(Q24641929)

2

0 references

T Bonny

3

0 references

K Adkison

4

0 references

L Curtis

5

0 references

J Millard

6

0 references

K Kabeya

7

0 references

N Clumeck

Antimicrobial Agents and Chemotherapy

8

0 references

language of work or name

English

0 references

publication date

March 2008

0 references

published in

0 references

volume

52

0 references

issue

3

0 references

page(s)

858-65

0 references

cites work

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Drug-related hepatotoxicity

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Outcome and prognostic markers in severe drug-induced liver disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Idiosyncratic drug hepatotoxicity

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Hepatotoxicity in drug development: detection, significance and solutions

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Lack of chemokine receptor CCR5 promotes murine fulminant liver failure by preventing the apoptosis of activated CD1d-restricted NKT cells.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2258506

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

28 November 2018

1 reference

12 December 2020

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management

1 reference

12 December 2020

Novel HIV treatment approved

1 reference

12 December 2020

CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice

1 reference

12 December 2020

Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period

1 reference

Crossref

https://api.crossref.org/works/10.1128%2FAAC.00821-07

7 January 2021